Sun Pharmaceutical Industries Limited has announced a strategic agreement to acquire Organon & Co, a move set to transform its global footprint. The transaction, valued at an enterprise value of $11.75 billion, will integrate Organon’s established brand portfolio, biosimilars, and strong women’s health franchise into Sun Pharma’s operations. The acquisition is expected to nearly double revenues to $12.4 billion and enhance Sun’s presence across 140+ countries upon completion in early 2027.
A Transformative Global Acquisition
In a significant expansion of its global capabilities, Sun Pharmaceutical has entered into a definitive agreement to acquire Organon & Co. This transaction marks a major milestone in Sun Pharma’s journey toward becoming a top 25 global pharmaceutical company. By combining strengths, the entity aims to unlock $350 million in potential synergies within 2 to 4 years following the deal’s closing.
Enhanced Portfolio and Innovation
The acquisition brings highly complementary assets into the fold. Organon contributes a strong platform in Women’s Health, which will become a new pillar for Sun Pharma, alongside a top-tier biosimilars platform and a portfolio of 50+ established brands. The combined business expects to derive 27% of its revenue from Innovative Medicines and 51% from established brands and branded generics, creating a diversified and robust revenue stream.
Financial Impact and Future Growth
Financially, the merger is set to generate significant scale. Post-consolidation, the combined entity targets total revenues of approximately $12.4 billion. Furthermore, the merger is projected to nearly double the combined EBITDA to $3.7 billion and free cash flow to $2.5 billion. This strong cash position is designed to facilitate debt repayment while fueling continued investment in high-growth therapy areas.
Strategic Market Expansion
The deal significantly strengthens Sun Pharma’s geographic reach. The combined entity will boast a 24,000+ strong commercial front-end team, providing improved access to markets in Europe, China, Korea, Mexico, and Thailand. With 18 major markets each contributing over $100 million in revenue, the company is well-positioned to leverage its global infrastructure to drive long-term value creation.
Transaction Details
The acquisition is valued at an enterprise value of $11.75 billion, with an equity value of $3.99 billion. Sun Pharma plans to fund the transaction using $2–2.5 billion of cash on hand and $9.25–9.75 billion in committed bank financing. The deal is expected to finalize in early 2027, pending shareholder approval and customary regulatory clearances.
Source: BSE
